首页> 外文OA文献 >Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
【2h】

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers

机译:Her2neu阳性(非腔)内在乳腺癌亚型的临床和预后剖面:与Her2neu阳性腔乳腺癌的比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Abstract Objective Her2neu receptor is proto-oncogene which can be over-expressed in both luminal and non-luminal breast cancers. In the present study, we aimed to compare the prognostic and predictive factors like tumor grade, T-stage, N-stage and ki67 index in Her2neu intrinsic breast cancer subtype with Her2neu over-expressed luminal breast cancers. Results 801 (41%) cases were Her2neu positive; out of which, 418 cases (52.2%) showed ER positivity and thus were classified as Her2neu positive luminal cancers whereas 383 cases (47.8%) were ER and PR negative and therefore were labeled as intrinsic Her2neu subtype (non-luminal). Her2neu positive (non-luminal) cancers were significantly associated with higher grades and Ki67 proliferative index compared to Her2neu positive luminal cancers. On the other no significant association was noted in T-stage and N-stage. We found a high frequency of her2neu positivity in our studied population of breast cancer. Moreover, association of her2neu positive (non-luminal) breast cancers with higher grade and ki67 index indicates a predictive value of ER/PR positivity in her2neu positive breast cancers. On the other hand, lack of association with respect to T and N stage, signifies no prognostic benefit of ER/PR in her2neu positive breast cancers.
机译:摘要目的Her2neu受体是原癌基因,可以在腔和非腔乳腺癌中过度表达。在本研究中,我们旨在比较Her2neu内在乳腺癌亚型的肿瘤等级,T-阶段,N-阶段和KI67指数等预后和预测因素与Her2neu过度表达的腔乳腺癌。结果801(41%)病例是Her2neu阳性;其中418例(52.2%)显示ER积极性,因此被归类为Her2neu阳性腔癌,而383例(47.8%)是ER和Pr阴性,因此标记为内在的Her2neu亚型(非腔)。与Her2Neu阳性腔癌相比,Her2neu阳性(非腔)癌症与较高的等级和Ki67增殖性指数显着相关。另一方面,在T-阶段和N阶段没有发现任何重要关联。在我们研究的乳腺癌人群中,我们发现了高频率的Her2neu积极性。此外,HER2NEU阳性(非腔)乳腺癌具有较高等级和KI67指数的关联表明HER2NEU阳性乳腺癌中ER / PR阳性的预测值。另一方面,与T和N阶段缺乏关联,表示HER2NEU阳性乳腺癌中ER / PR的预后益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号